Annovis Hits Full Enrollment in Pivotal Phase 3 AD Trial, But Funding Overhang Persists

What happened

Annovis Bio announced full enrollment of its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease with 850 patients, exceeding original projections. The company now targets symptomatic data readout in Q1 2027 and disease-modifying data in Q1 2028, setting up potential two NDA submissions. While this removes a key operational risk, the master report highlighted that the company's cash runway only extends to Q3 2026, meaning additional financing is still required to bridge to these readouts. The enrollment milestone does not fundamentally alter the bearish case that equity value is highly dependent on the company's ability to raise capital on non-punitive terms amid going-concern risk. As such, the news is incrementally positive but does not resolve the core investment thesis focused on financing and execution risk.

Implication

Successful enrollment de-risks trial completion, but investors should wait for a clearer funding catalyst or a more attractive entry point before building a position.

Thesis delta

The master thesis flagged enrollment stagnation as a key risk; full enrollment reduces that risk, shifting the probability distribution slightly toward the base and bull scenarios. However, the financing overhang and need for non-punitive capital remain unchanged, and the company still faces NYSE compliance and data readout timelines that require additional funding. The risk-reward has modestly improved but is not sufficient to upgrade from WAIT.